Gongwin Biopharm Holdings Co., Ltd. (TPEX:6617)

Gongwin Biopharm Holdings Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	921.78	893.47	273.59	671.51	454.12	707.23
Short-Term Investments	617.54	848.99	668.66	434.1	372.2	297.09
Trading Asset Securities	477.84	466.79	-	-	-	34.41
Cash & Short-Term Investments	2,017	2,209	942.25	1,106	826.33	1,039
Cash Growth	114.96%	134.47%	-14.78%	33.80%	-20.45%	60.78%
Accounts Receivable	15.39	14.17	10.58	-	-	-
Other Receivables	17.1	12.31	4.52	4.25	0.06	0.21
Receivables	32.49	26.48	15.1	4.25	0.06	0.21
Inventory	3.16	3.59	11.93	0.21	-	-
Prepaid Expenses	13.38	12.89	11.36	11.11	-	-
Other Current Assets	182.93	180.62	138.42	215.88	93.74	21.34
Total Current Assets	2,249	2,433	1,119	1,337	920.12	1,060
Property, Plant & Equipment	329.54	330.89	118.32	245.05	246.76	136.97
Long-Term Investments	509.18	497.81	156.61	32.35	3.88	5.34
Other Intangible Assets	0.35	0.37	0.19	-	-	0.01
Other Long-Term Assets	120.18	120.3	121.17	7.47	1.12	1.42
Total Assets	3,208	3,382	1,515	1,622	1,172	1,204
Accounts Payable	0.17	0.21	0.29	-	-	-
Accrued Expenses	16.92	28.51	26.37	32.63	21.97	19.03
Short-Term Debt	115.07	110.63	75.02	134.55	113.06	29.28
Current Portion of Leases	3.26	3.21	2.12	5.01	1.99	4.7
Current Income Taxes Payable	16.03	15.7	15.13	15.44	15.2	-
Other Current Liabilities	5.9	23.9	7.44	3.62	2.54	2.66
Total Current Liabilities	157.35	182.16	126.36	191.26	154.75	55.66
Long-Term Leases	12.25	12.91	0.03	2.18	0.1	2.11
Long-Term Unearned Revenue	44.77	45.01	45.08	42.03	29.57	27.97
Other Long-Term Liabilities	40.01	41.76	32.06	13.24	0	-
Total Liabilities	254.38	281.84	203.53	248.7	184.43	85.75
Common Stock	1,275	1,275	1,133	1,131	1,099	1,093
Additional Paid-In Capital	3,500	3,500	1,644	1,634	1,061	1,045
Retained Earnings	-1,544	-1,529	-1,441	-1,349	-1,094	-972.88
Treasury Stock	-331.92	-166.61	-	-	-	-
Comprehensive Income & Other	62.3	27.14	-21.35	-24.77	-95.34	-71.36
Total Common Equity	2,962	3,107	1,315	1,392	970.72	1,093
Minority Interest	-7.59	-6.2	-3.68	-18.58	16.74	25.21
Shareholders' Equity	2,954	3,100	1,312	1,373	987.45	1,118
Total Liabilities & Equity	3,208	3,382	1,515	1,622	1,172	1,204
Total Debt	130.59	126.75	77.17	141.74	115.14	36.09
Net Cash (Debt)	1,887	2,082	865.08	963.87	711.19	1,003
Net Cash Growth	120.90%	140.73%	-10.25%	35.53%	-29.07%	61.07%
Net Cash Per Share	15.25	17.24	7.64	8.67	6.49	9.60
Filing Date Shares Outstanding	124.62	126.06	113.34	113.09	109.92	109.27
Total Common Shares Outstanding	124.62	126.06	113.34	113.09	109.92	109.27
Working Capital	2,092	2,251	992.7	1,146	765.37	1,005
Book Value Per Share	23.77	24.64	11.61	12.31	8.83	10.00
Tangible Book Value	2,961	3,106	1,315	1,392	970.72	1,093
Tangible Book Value Per Share	23.76	24.64	11.61	12.31	8.83	10.00
Land	228.65	228.65	49.69	155	155	49.69
Buildings	75.8	75.29	52.95	69.59	69.23	53.22
Machinery	75.45	73.96	63.43	56.76	54.91	54.13
Construction In Progress	-	-	-	-	0.54	-
Leasehold Improvements	-	-	3.75	3.75	3.75	3.75

Source: S&P Global Market Intelligence. Standard template. Financial Sources.